Literature DB >> 12149650

PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.

Yong Choi1, Jie Zhang, Cristina Murga, Hong Yu, Erich Koller, Brett P Monia, J Silvio Gutkind, Weiqun Li.   

Abstract

Expression of PTEN tumor suppressor gene has been known to dephosphorylate the phosphatidylinositol 3' kinase (PI3K) products on the 3 prime inositol ring, resulting in reduced Akt activation. Loss of PTEN expression in OPM2 and delta47 human myeloma lines led to high Akt activity toward insulin-like growth factor I (IGF-I). In contrast, mouse plasma cell tumor (PCT) lines, expressing wild type PTEN, did not respond to IGF-I for Akt activation. We demonstrated here that endogenous PTEN played a negative role in controlling Akt activity in both mouse PCT and NIH3T3 fibroblast lines by using anti-sense oligonucleotides against PTEN. To determine the role of src-homology 2-containing inositol 5' phosphatase (SHIP) in regulating the PI3K/Akt pathway, we manipulated its expression by down-regulation and overexpression in myeloma, PCT and NIH3T3 lines and analysed Akt activation. Our results showed that SHIP, unlike PTEN, did not affect Akt activity in all systems analysed, despite its ability to dephosphorylate a PI3K product. Although SHIP2 expression resulted in suppression of interleukin-6-mediated mitogen-activated protein kinase activation, expression of SHIP and SHIP2 in a PTEN-null myeloma line did not suppress Akt activity. Biologically, expression of only PTEN, but not SHIP and SHIP2, resulted in growth inhibition and increased apoptosis in OPM2 myeloma line. Together, our results have established the role of PTEN, but not SHIP and SHIP2, in negatively regulating the PI3K/Akt cascade and in myeloma leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149650     DOI: 10.1038/sj.onc.1205650

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Neuronal Cbl controls biosynthesis of insulin-like peptides in Drosophila melanogaster.

Authors:  Yue Yu; Ying Sun; Shengqi He; Cheng Yan; Liangyou Rui; Wenjun Li; Yong Liu
Journal:  Mol Cell Biol       Date:  2012-07-09       Impact factor: 4.272

Review 2.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

3.  Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Authors:  Nikoletta Lendvai; Andrew J Yee; Ioanna Tsakos; Aeri Alexander; Sean M Devlin; Hani Hassoun; Neha Korde; Alexander M Lesokhin; Heather Landau; Sham Mailankody; Guenther Koehne; David J Chung; Ola Landgren; Noopur S Raje; Sergio Giralt
Journal:  Blood       Date:  2016-03-28       Impact factor: 22.113

4.  The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery.

Authors:  Biyin Cao; Xinliang Mao
Journal:  Am J Blood Res       Date:  2011-05-25

Review 5.  Targeting the bone marrow in Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Yong Zhang; Yang Liu; Hai Ngo; Feda Azab; Antonio Sacco; Abdelkareem Azab; Patricia Maiso; Brittany Morgan; Phong Quang; Ghayas C Issa; Xavier Leleu; Aldo M Roccaro
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-30

6.  SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.

Authors:  Jessica A Gasser; Hiroyuki Inuzuka; Alan W Lau; Wenyi Wei; Rameen Beroukhim; Alex Toker
Journal:  Mol Cell       Date:  2014-10-30       Impact factor: 17.970

7.  Defining the role of TORC1/2 in multiple myeloma.

Authors:  Patricia Maiso; Yi Liu; Brittany Morgan; Abdel Kareem Azab; Pingda Ren; Michel B Martin; Yong Zhang; Yang Liu; Antonio Sacco; Hai Ngo; Feda Azab; Phong Quang; Scott J Rodig; Charles P Lin; Aldo M Roccaro; Christian Rommel; Irene M Ghobrial
Journal:  Blood       Date:  2011-11-01       Impact factor: 22.113

Review 8.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

Review 9.  The Role of PI3K/Akt and ERK in Neurodegenerative Disorders.

Authors:  Sachchida Nand Rai; Hagera Dilnashin; Hareram Birla; Saumitra Sen Singh; Walia Zahra; Aaina Singh Rathore; Brijesh Kumar Singh; Surya Pratap Singh
Journal:  Neurotox Res       Date:  2019-02-01       Impact factor: 3.911

10.  High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).

Authors:  Jieru Meng; Henry Peng; Bingbing Dai; Wei Guo; Li Wang; Lin Ji; John D Minna; Christine M Chresta; Paul D Smith; Bingliang Fang; Jack A Roth
Journal:  Cancer Biol Ther       Date:  2009-11-18       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.